Document Detail

Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
MedLine Citation:
PMID:  16874158     Owner:  NLM     Status:  MEDLINE    
AIMS: The objective of this study is to determine the status of major risk factors for coronary heart disease in patients with established coronary heart disease in Croatia and whether the Joint European Societies' recommendations on coronary heart disease prevention are being followed in Croatia and whether secondary prevention practices have improved between 1998 and 2003. METHODS: Five surveys were undertaken in 35 centres covering the geographical area of the whole of Croatia between 1 June, 1998 and 31 March, 2003. Consecutive patients of both sexes were identified after coronary-bypass grafting or a percutaneous transluminal coronary angioplasty or a hospital admission with acute myocardial infarction or ischaemia. Data collection was based on a review of medical records and the methodology used was similar to the one used in the EUROASPIRE study. RESULTS: Fifteen thousand, five hundred and twenty patients were enrolled (64.6% men); 35% of patients smoked cigarettes, 66% had raised blood pressure, 69% elevated serum total cholesterol, 69% elevated serum low-density lipoprotein (LDL) cholesterol, 42% low high-density lipoprotein (HDL) cholesterol, 37% elevated triglycerides, 30% diabetes and 34% family history of coronary heart disease. More men were smokers and had low HDL cholesterol, but more women had elevated total and LDL cholesterol, hypertension and diabetes. More men had Q wave acute myocardial infarction, but more women had angina. Over 5 years, the prevalence of hypercholesterolemia decreased substantially from 82.7 to 65%. Eighty-three percent of patients received aspirin and this percentage did not change during the study. The use of diuretics, calcium antagonists and nitrates did not change either. The reported use of statins, angiotensin-converting enzyme inhibitors and beta-blockers increased significantly. CONCLUSION: This survey shows a high prevalence of modifiable risk factors in Croatian patients with coronary heart disease. Although the higher use of statins, angiotensin-converting enzyme inhibitors and beta-blockers is encouraging, the fact that most coronary heart disease patients are still not achieving the recommended goals remains a concern. There is real potential to reduce the very high coronary heart disease morbidity and mortality in Croatia.
Zeljko Reiner; Sime Mihatov; Davor Milicić; Mijo Bergovec; Danijel Planinc;
Related Documents :
12818418 - Autoantibodies against modified low-density lipoproteins in coronary artery disease.
20601648 - Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of stat...
19001358 - Pltp activity is a risk factor for subsequent cardiovascular events in cad patients und...
20602558 - Cholesterol and cardiac arrhythmias.
18245658 - Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major.
2943958 - Plasma and atrial content of atrial natriuretic factor in cardiomyopathic hamsters.
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology     Volume:  13     ISSN:  1741-8267     ISO Abbreviation:  Eur J Cardiovasc Prev Rehabil     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-28     Completed Date:  2006-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101192000     Medline TA:  Eur J Cardiovasc Prev Rehabil     Country:  England    
Other Details:
Languages:  eng     Pagination:  646-54     Citation Subset:  IM    
Department of Internal Medicine, University Hospital Centre Zagreb, Croatia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use*
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Cholesterol / blood
Coronary Disease / blood,  epidemiology,  prevention & control*
Croatia / epidemiology
Follow-Up Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Middle Aged
Retrospective Studies
Risk Factors
Survival Rate / trends
Treatment Outcome
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of home-based cardiac exercise program on the exercise tolerance, serum lipid values and sel...
Next Document:  A functional polymorphism in the lymphotoxin-alpha gene is associated with carotid artery wall thick...